← European Medicine Shortage Tracker · all medicines

Candesartan hidroclorotiazida shortage — availability across Europe

Name: European Medicine Shortage Tracker dataset
Creator: MobiDoctor
License: https://creativecommons.org/licenses/by/4.0/

Availability information only — Mobi Doctor doesn't sell medicines; check with a pharmacy.

MEDICALLY REVIEWED

Dr. Chrysoula I. Liakou MD, PhD

Internal Medicine Specialist
Cancer Immunology Researcher

Reviewed 30 July 2026 · next review due 30 January 2027

Candesartan hidroclorotiazida currently has availability issues reported in 2 European registers: Spain, Italy.

Shortage ATC — · also listed as: CANDESARTAN HIDROCLOROTIAZIDA · CANDESARTAN + IDROCLOROTIAZIDE · data refreshed 9 September 2026

Key facts

As of 9 September 2026, Candesartan hidroclorotiazida has active availability issues in 2 of 9 tracked European registers.
Registers reporting issues: Spain, Italy.
Latest expected-resolution date on file: 2027-03-08.
Longest-running open report: since 2026-02-09 (7 months, Italy).
Data source: 2 official medicines-agency registers, refreshed daily.

As of 9 September 2026, 2 of the 9 tracked registers list current availability issues for Candesartan hidroclorotiazida, covering 4 affected product presentations. The longest-running open report was filed in Italy on 2026-02-09 and has now been open for about 7 months. Where agencies state a cause, manufacturing problems lead with 3 of the 3 stated-cause reports. The furthest expected-resolution date currently on file is 2027-03-08; the earliest is 2027-03-08. Momentum is current, not historical: 2 of the open reports were filed within the last 90 days. Registers in Spain, Italy indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching.

Where	Status & products	Since	Expected end	Reason / alternatives	Source
🇪🇸 Spain	Shortage CANDESARTAN/HIDROCLOROTIAZIDA VIATRIS 16 MG/12,5 MG COMPRIMIDOS EFG, 28 comprimidos	2026-04-05	2027-03-08	Existen otros medicamentos con los mismos principios activos y misma vía. Alternatives: Existe/n otro/s medicamento/s con los mismos principios activos y para la misma vía de administración.	register ↗
🇮🇹 Italy	Shortage CANDESARTAN E IDROCLOROTIAZIDE EG STADA + 2 more products CANDESARTAN E IDROCLOROTIAZIDE MYLAN CANDESARTAN E IDROCLOROTIAZIDE MYLAN	2026-02-09	—	Problemi produttivi Alternatives: AIFA: equivalents with the same active substance are available.	register ↗

New register reports per month

Full report history (4 register entries)

Every individual register entry for Candesartan hidroclorotiazida in the tracked sources, newest first — including resolved and discontinued reports.

Reg.	Product	Status	Reported	Expected end	Stated reason
🇮🇹 IT	CANDESARTAN E IDROCLOROTIAZIDE MYLAN	Shortage	2026-08-17	—	Problemi produttivi
🇮🇹 IT	CANDESARTAN E IDROCLOROTIAZIDE EG STADA	Shortage	2026-08-12	—	Problemi produttivi
🇪🇸 ES	CANDESARTAN/HIDROCLOROTIAZIDA VIATRIS 16 MG/12,5 MG COMPRIMIDOS EFG, 2	Shortage	2026-04-05	2027-03-08	Existen otros medicamentos con los mismos principios activos
🇮🇹 IT	CANDESARTAN E IDROCLOROTIAZIDE MYLAN	Shortage	2026-02-09	—	Problemi produttivi

Frequently asked

Is Candesartan hidroclorotiazida currently in shortage in Europe?

Yes. As of 9 September 2026, availability issues are reported in: Spain, Italy. Availability is national — a shortage in one country does not mean it is short everywhere.

When is the Candesartan hidroclorotiazida shortage expected to end?

Agency prognoses on file range from 2027-03-08 to 2027-03-08. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.

Are there alternatives to Candesartan hidroclorotiazida?

4 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.

Where does this Candesartan hidroclorotiazida availability data come from?

Directly from the official medicines-agency registers that list Candesartan hidroclorotiazida: AEMPS CIMA (Spain), AIFA (Italy). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.

Embed this tracker

Pharmacies, patient sites and newsrooms are welcome to embed the live status of Candesartan hidroclorotiazida — free, with attribution. Copy this snippet:

<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/candesartan-hidroclorotiazida/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Candesartan hidroclorotiazida availability in Europe"></iframe>
<p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/candesartan-hidroclorotiazida/">Candesartan hidroclorotiazida shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>

Cite: “Candesartan hidroclorotiazida: availability status across 2 European registers — European Medicine Shortage Tracker (MobiDoctor), 9 September 2026.” Link this page and the agency record. Statuses come from the linked official registers and can change daily.